Cordis Revolutionizes CAD Treatments With SELUTION Trials at TCT 2025 Cordis has unveiled groundbreaking results from the SELUTION DeNovo and SELUTION4ISR trials at TCT 2025, reshaping treatments for coronary artery disease.

Cordis Revolutionizes CAD Treatments With SELUTION Trials at TCT 2025 #USA #Miami_Lakes #Cordis #SELUTION_SLR #CAD_Treatments

Cordis Reveals 12-Month Outcomes of SELUTION SLR™ Trials at TCT 2025 Cordis will present groundbreaking 12-month data from two key randomized clinical trials involving SELUTION SLR™ DEB at TCT 2025, showcasing advances in cardiovascular care.

Cordis Reveals 12-Month Outcomes of SELUTION SLR™ Trials at TCT 2025 #USA #San_Francisco #Cardiovascular #Cordis #SELUTION_SLR

Cordis Unveils Ambitious Global Registry for Drug-Eluting Balloons, Enrolling 10,000 Patients Cordis has launched the SELUTION Global Coronary Registry, aiming to enroll 10,000 patients to enhance our understanding of drug-eluting balloon technology, SELUTION SLR™.

Cordis Unveils Ambitious Global Registry for Drug-Eluting Balloons, Enrolling 10,000 Patients #USA #Miami_Lakes #Cordis #SELUTION_SLR #Drug-Eluting_Balloons

Cordis Reports Groundbreaking Efficacy of SELUTION SLR™ in Treating Complex Peripheral Artery Disease Cordis has unveiled impressive results from two major studies, affirming the durability of SELUTION SLR™ in addressing complex PAD, achieving significant patient outcomes.

Cordis Reports Groundbreaking Efficacy of SELUTION SLR™ in Treating Complex Peripheral Artery Disease #USA #Peripheral_Artery_Disease #Miami_Lakes #Cordis #SELUTION_SLR